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Abstract: 
Fatty acid synthase (FAS), a 272 kDa protein complex regulated via the sterol regulatory binding 
element protein (SREBP) pathway, is implicated in intracellular de novo synthesis of fatty acids and is 
overexpressed in a variety of human epithelial tumors, including ovarian cancer. FAS demonstrates a 
role in mediating cellular proliferation, survival, and migration and invasion, while decreasing the rate 
of apoptosis within the cells, especially when upregulated. The goal of the present study is to 
investigate the role of FAS-mediated drug resistance in ovarian cancer cells. The results I have 
procured in recurrent ovarian cancer cell (ROCC) lines show a marked overexpression of FAS in 
human ovarian tumor samples and resistant ovarian cancer cell lines to be correlated with decreased 
apoptosis and increased cell migration. In addition, the FAS inhibitor cerulenin, in combination with 
cisplatin, causes significant induction of apoptosis and migratory inhibition in drug-resistant ovarian 
cancer cells. Therefore, I hypothesize that a mechanism by which ovarian cancer cells develop drug 
resistance is by upregulating the FAS pathway, allowing the increased metabolic demands of the 
cancer cells to be met. This pilot study suggests that targeting molecular FAS using a small molecule 
inhibitor may have therapeutic potential for treating drug-resistant ovarian cancer. 
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Background: 
Ovarian cancer 
Amongst all of the gynecologic diseases, ovarian cancer is the leading cause of death with an 
average survival of five years after diagnosis and an estimated malignancy rate of just under 70%, 
according to the Foundation for Women’s Cancer. Due to the common late-stage diagnosis of ovarian 
cancer, tumor resection followed by taxane- or platinum-based adjuvant combination chemotherapy 
treatment is standard protocol; however, around 75% of patients relapse within two years of treatment 
and qualify for treatment of tumor recurrence (1, 2). Two common chemotherapeutic agents used in 
combination therapy are paclitaxel, a taxane-based chemotherapeutic, and cis-diaminedichloro 
platinum II (CDDP) (Figure 1), a platinum-based chemotherapeutic. A problem that routinely arises in 
relapsed patients is the development of a platinum-resistant recurrent tumor, thus begetting a 
narrowed scope of effective therapeutic options. Consequently, a mechanistic understanding of 
chemotherapy resistance in ovarian cancer is pivotal in the advancement toward a cure.  
Hypothesis: Our hypothesis is that increased expression of FAS in ovarian cancer plays a central role 
in the development of resistance to anticancer therapy, and that targeting the FAS protein using 
small-molecule inhibitors will increase treatment success, regardless of cellular phenotype or tumor 
microenvironment. This will lead to decreased disease progression and improve patient prognosis. 
 
 
 
 
 
Acquired drug resistance in recurrent ovarian cancer: a threat to successful treatment 
Acquired drug resistance remains a major challenge in the clinical treatment of ovarian cancer. 
Cancer cells that survive exposure to common chemotherapy agents will develop a resistance to 
subsequent intervention (1) and the overall clinical response in chemotherapy-treated patients with 
recurrent ovarian cancer is only 40–60% (1,2). Therefore, the investigation and development of 
potential new therapeutic compounds is necessary in overcoming CDDP-mediated drug resistance in 
recurrent ovarian cancers.  
 
  
Figure 1: Cisplatin (CDDP) and 
Cerulenin, respectively. CDDP inhibits 
cancer growth by forming DNA adducts 
in target cells. Cerulenin acts to prevent 
cancer proliferation via inhibition of the 
N-terminal catalytic domain of FAS. 
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Fatty acid synthase 
FAS is a metabolic enzyme involved in the synthesis of long-chain saturated fatty acids that are 
essential for membrane synthesis in proliferating cells. The overexpression of FAS is a recently-
discovered phenomenon found in most ovarian cancer tissues, and the increased expression of this 
enzyme is associated with increased aggressiveness and poor patient survival. Increased expression 
of FAS occurs very early in ovarian cancer development and is more pronounced as the tumor 
progresses toward more advanced stages (4-6). As a result, FAS has emerged as a potential tumor 
marker for breast cancer and endometrial cancer, as well as a potential therapeutic target. We 
recently found that FAS is highly expressed in various human ovarian cancer cells and human tumor 
specimens, particularly in early stage disease (figure 3). Thus, it is logically supported that FAS 
expression may have potential as a prognostic indicator of ovarian cancer. 
 
Biological function of FAS 
Important in the regulation of endogenous fatty acid, cholesterol, and phospholipid synthesis, the 
SREBPs are a family of membrane-bound transcription factors located in the rough endoplasmic 
reticulum. There are three isoforms of SREBP known: SREBP-1a and SREBP-1c, which are 
generated from alternative splicing of the same gene on chromosome 17, as well as SREBP-2, which 
is located on chromosome 22 (3). When the cellular environment is deprived of lipid or sterol 
molecules, these SREBPs are activated in a proteolytic fashion by the SREBP-cleavage activating 
proteins (SCAP), which allows the activated SREBP to translocate into the nucleus and begin 
transcribing its target genes (3).  
 
Among the genes transcribed, the most notable are those involved in cholesterol biosynthesis, the 
modulation of low density lipoprotein (LDL) membrane receptors, which operate in a negative-
feedback loop, and those involved with fatty acid uptake and synthesis (FAS, acetyl CoA carboxylase, 
lipoprotein lipase) (3). With regard to cholesterol regulation, SREBPs upregulates LDL receptor 
production, which bind and endocytose extracellular cholesterol when endogenous cholesterol 
synthesis is not adequate to meet the cell’s metabolic needs; however, when the intracellular 
environment is saturated with cholesterol, each SREBP-encoding gene begins to cotranscribe 
miRNAs for its respective mRNA, effectively inhibiting translation (4). First implicated in the regulation 
of fatty acid synthesis in 1993, the SREBP pathway is now considered to be one of the master 
regulatory elements of the FAS pathway, however regulation of FAS independent of SREBP has also 
been observed. 
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Essential for the survival of cancer cells, FAS mediates de novo lipogenesis and the production of 
long-chain fatty acids, specifically palmitate, from precursor molecules procured from normal glucose 
metabolism, specifically citrate, acetyl-coenzyme A (CoA), and malonyl-CoA (5, 6). Through a series 
of enzymatic reactions, the carbohydrate precursors are converted into fatty acids, glycerol, and 
phospholipids utilized for biosynthesis of endogenous signaling molecules and components of the 
cytoplasmic membrane (5). In a typical cellular environment, fatty acids are not required in large 
quantities and, therefore, are not commonly synthesized endogenously; healthy cells are able to rely 
on the exogenous uptake of fatty acids to self-sustain growth (7). However, with the markedly 
increased metabolism of a tumor microenvironment, cancer cells often exhibit a shift from exogenous 
uptake of fatty acids to endogenous production of these molecules utilizing FAS (8). By producing 
endogenous fatty acids using FAS, the rapidly-proliferating cancer cells are able to meet the elevated 
demand for biosynthetic molecules needed for expanding the cytoplasmic membrane and for 
subsequent division. Intracellular production of long-chain fatty acids also provides a source of energy 
via -oxidation of lipids into metabolism precursor molecules, such as acetyl-CoA, NADH, and 
FADH2. Consequently, FAS plays a pivotal role in maintaining metabolism, proliferation and division 
pathways of cancer cells. 
 
Within the field of medicine, the development of targeted therapies is a rapidly-expanding topic of 
interest and recent research suggests FAS as being a potential therapeutic target for inhibition of 
tumor growth (6). Inhibitors of FAS have been shown to induce apoptosis in cancerous cell lines in 
vitro, to delay both benign and malignant tumor growth in vivo, and to decrease the rate of formation 
of ascites in vivo; however, the mechanisms of action of many of these inhibitors are poorly 
understood (6). One inhibitor in particular whose mechanism has been delineated, cerulenin, has 
provided promising direction regarding the future of targeted FAS inhibition by demonstrating specific 
intratumor activity within just 6 hours of administration in vivo. In addition to demonstrating effective 
bio-absorption in vivo, Cerulenin is also shown to be selectively cytotoxic to cancer cells with an 
increased demand for fatty acid biosynthesis as opposed to non-cancerous cells in vitro (9). 
 
Inhibiting ovarian cancer proliferation and migration 
Cerulenin (2,3-Epoxy-4-oxo-7,10-dodecadienoylamide) (Figure 1), an early, small-molecule inhibitor 
of FAS, is a common means by which the role of FAS is studied in the laboratory. Of the six catalytic 
domains of FAS, the N-terminal -ketoacyl synthase (KS) domain is most commonly targeted by 
FAS inhibitors, including cerulenin (10, 11). The structure of cerulenin includes an epoxide as its 
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active functional group which inhibits the FAS KS activity. The instability of the epoxide allows the 
cerulenin to attack the active site of KS and covalently binds to the sulfur on the Cysteine 1305 
residue on the FAS protein (12). The KS domain of FAS is typically orchestrates a condensation 
reaction between acetyl-CoA and malonyl-CoA and catalyzes the formation of the fatty acid palmitate, 
which can be metabolized and used in various biosynthetic reactions (13). Due to this inhibition of the 
KS catalytic domain, palmitate synthesis and subsequent metabolism and energy production are 
discontinued (6, 13). 
 
In addition to serving as a means by which cancer cells are able to meet increased metabolic 
demands, FAS has been implicated in mediating chemotherapy resistance within cancer cells, though 
the mechanism remains largely ambiguous. CDDP is a platinum coordination compound with a 
square-planar geometry, which was initially investigated as a cancer chemotherapy in 1965 when it 
was found to inhibit cell division in E. coli (14). CDDP enters cells via transport proteins (15) or 
passive permeation through the cytoplasmic membrane and induces apoptosis in cancer cells by 
targeting the nucleus upon entering the cell and forming strong intra- and inter-strand DNA adducts, 
effectively preventing transcription and replication (16, 17). While being a treatment option for an 
array of cancers, one of the major obstacles to CDDP being an effective therapy is the development 
of chemoresistance in its target cancer cells. This resistance to platinum agents has been attributed a 
few different mechanisms: reduced intracellular drug accumulation, whether due to reduced cisplatin 
uptake or increased cisplatin efflux (18-20); glutathione-mediated intracellular cisplatin inactivation 
and detoxification (21); and increased DNA repair by nucleotide excision repair (22). Dirk O 
Bauerschlag et al. demonstrated that FAS expression at both the protein and mRNA levels in cancer 
cells was up to 100-fold that of the FAS expression in healthy cells and, as predicted, when treating 
both CDDP-resistant and -sensitive cell lines with a treatment regimen of CDDP, higher rates of 
apoptosis and decreased cell viability were observed in sensitive cells while the opposite was 
observed in resistant cells.  
 
The information presented above has inspired the current project, which is to not only investigate the 
mechanism underlying cisplatin resistance in ovarian cancer, but to also explore the pathway in 
relation to FAS; these preliminary in vitro wound-healing, western blotting, annexin V (apoptosis 
assay), and ex vivo immunohistochemistry (IHC) results have been verified in replicates. Based upon 
previous research and the current results, I hypothesize that FAS not only plays a substantial role in 
the development of resistance to anticancer therapy in ovarian cancer cells, increasing the 
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survivability of cancer cells, but it also acts to inhibit the mechanism by which CDDP induces 
apoptosis, directly or indirectly. While the mechanism is not explored in depth in this paper, these 
results provide promising support that FAS impedes upon the CDDP-mediated apoptosis pathway in 
ovarian cancer cells. 
 
Methods: 
Immunoblot 
TR127 cells, a ROCC line, were cultured to 60% confluence in supplemented RPMI medium (10% 
FBS, 1% PS, 1% sodium pyruvate) and arbitrarily placed into one of eight groups: control, CDDP 
10M treated, cerulenin 20M treated, and CDDP 10M + cerulenin 20M concomitant treatment; or 
control, CDDP 5M, CDDP 10M, and CDDP 20M. After 24 hours of treatment, the cells were 
collected via scraping and centrifuged at 1,200 RPM, the pellet was subjected to 30 minutes of lysing 
(200 L, TN1 lysis buffer with 1x ThermoFisher Halt protease inhibitor [EDTA 0.005 mM, AEBSH HCL 
1mM, aprotinin 0.8 mM, bestatin 0.05 mM e-64 0.015 mM, leupeptin 0.02 mM, pepstatin A 0.01 mM]) 
and was centrifuged at 10,500 RPM. The protein was collected and quantified using ThermoFisher 
Pierce protein assay kit (catalog: 23225) and a spectrophotometer reading absorbance at 562 nm. 
After quantification, 30g protein of each sample were added to sample buffer and denatured at 98C 
for 8 minutes. The denatured samples were loaded into BioRad mini gels (catalog: 4568081) and ran 
under denaturing, SDS-containing conditions at 100 V for 2 hours. The protein was transferred from 
the SDS gel onto a nitrocellulose membrane in 1x tris-glycine buffer and 20% methanol at 100V for 2 
hours. The resulting proteins were analyzed using an HRP-detecting chemi-luminescence kit (GE, 
catalog: RPN2232) and developed using autoradiographic film (Denville, catalog: E3018) in an x-ray 
developer.  
 
Migration 
100,000 TR127 cells were seeded into 6-well plates in supplemented RPMI medium. Once the cells 
reached 95% confluence, a 10L cell culture tip was used to scratch three lines in each well, the 
existing medium was removed, and the wells were labeled accordingly: zero hour (RPMI), 24-hour 
control (RPMI), CDDP 5M, CDDP 10M, CDDP 20M, cerulenin 20M, CDDP 10M + cerulenin 
20M. 2mL of RPMI medium containing each treatment was added to its respective well. Pictures 
were immediately taken of the zero-hour (RPMI) control scratches. After 24 hours elapsed, pictures of 
the 24-hour positive control, CDDP 5M, CDDP 10M, CDDP 20M, cerulenin 20M, and CDDP 
10M + cerulenin 20M were taken. The wound areas remaining after 24 hours of treatment were 
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quantified using ImageJ software. Each measurement was taken in triplicate. Results are reported as 
the inverse of the average area remaining with standard deviation calculated. 
 
IHC 
Ex vivo CDDP-sensitive and -resistant high-grade, serous, ovarian carcinoma tumor tissues were 
collected from human patients with IRB approval. The tissues were embedded in optimal cutting 
temperature (OCT) medium (Sakura, catalog 4583) and stored at -80°C until sectioning. Sectioned 
slides (8m thickness) were then obtained following previously-described methods(23).  
 
Annexin V apoptosis analysis 
TR127 ROCC lines were cultured to 65% confluence in 10mm plates in RPMI medium and 
subsequently exposed to one of the following treatments: CDDP 10M, cerulenin 20M, or 
combination treatment. After 24 hours, apoptotic cells were measured via flow cytometry (EPICS 
Profile II flow cytometer; Coulter Corp., Hialeah, FL)  according to the ThermoFisher Annexin V 
staining protocol (catalog: V13241). 
 
Results:  
FAS/FAK expression in ovarian cancer:  
Figure 2 shows a comparison of basal levels of FAS and FAK in a cisplatin-sensitive (CS) cell line 
relative to those in cisplatin- (CR) or multi-drug-resistant (MDR) cell lines run in our lab. In addition to 
these in vitro results, ex vivo fluorescent and non-fluorescent IHC results performed using CDDP-
sensitive and -resistant human ovarian tumor 
tissues revealed a significant correlation between 
FAS expression level and cisplatin resistance. As 
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Figure 2: Basal, endogenous FAS (and FAS-
activated FAK) expression in drug-resistant 
human ovarian cancer cell lines (25). 
Figure 3: FAS (green, brown) in cisplatin-resistant 
ovarian tumors compared to that of cisplatin-
sensitive tissue. CS: (p=0.0025) CR: (p=0.0156) 
(N=6 CS, N=4 CR). 
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seen in figure 3, sensitive tissues (upper and lower left) exhibit much lower FAS expression (green 
and brown staining) as compared to those sections taken from resistant tissues (four remaining 
images). 
Cisplatin treatment enhances FAS/FAK and its target genes 
The CDDP optimization treatments demonstrated the ideal concentration of CDDP as being 10M, 
which corresponds with the recommended clinical dose. When subjected to either 5M, 10M, or 
20M, and collected for protein analysis, TR127 cells express the highest levels of FAS, cyclin D2, 
survivin, focal adhesion kinase (FAK), survivin, cyclic myc, vascular endothelial growth factor (VEGF), 
and matrix metallopeptidase 2 (MMP2) when treated with 10M CDDP as compared to the control, 
untreated cells (figure 4). Western blotting results have consistently found that with the treatment 
regimens, the levels of apoptotic proteins consistently increased in this order (from lowest measured 
apoptosis to highest measured apoptosis): control, CDDP 10M, cerulenin 20M, CDDP 10M + 
cerulenin 20M; while demonstrating increasing FAS expression in this order: cerulenin, 
CDDP/cerulenin, control, CDDP (figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PARP 
Cleaved PARP 
FAS 
-actin 
Figure 5: Western blot using TR127 
cells to study the effect on expression 
of FAS (metabolic activity and 
migration) and cleaved PARP 
(involved in apoptosis) following 
treatment with CDDP, the 
chemotherapeutic agent to which 
TR127 cells are resistant; or cerulenin, 
the FAS inhibitor. 
Figure 4: Western blot using TR127 cells to 
study the effect on expression following 
treatment with CDDP, the chemotherapeutic 
agent to which TR127 cells are resistant. 
Notable increase in FAS and FAK (both 
involved in migration), as well as survivin 
(protects cells proliferation), and MMP2 
(involved in cell invasion). 
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Targeting FAS via small molecule inhibitor 
Visually and quantitatively, in vitro wound-healing assays also showed that with an increase in CDDP 
concentration, there was an increase in migratory ability. When the concentration was increased from 
0 µM to 5 µM to 10 µM, optimal concentration of CDDP was found to be 10M, which is equivalent to 
the translated clinical dose. However, when cerulenin, the FAS inhibitor, was added concomitantly the 
cells, both cell viability and migratory ability were decreased (figure 6). Further, confirmation of these 
effects of FAS inhibition by cerulenin can be seen in a previous publication that was also published by 
our lab; however in place of cerulenin, siRNA was used to inhibit FAS expression (24). 
Evaluating apoptosis 
Analysis of cellular apoptosis was carried out using annexin V and propidium iodide stains. TR127 
cells were cultured in 10cm culture plates, exposed to 24 hours of treatment and then subjected to a 
combination of annexin V (tags live cells) and propidium iodide (tags dead, or late apoptotic cells). 
Figure 6: (Upper Left) This bar graph shows the average migration of TR127 cells after a 24-hour wound-
healing assay as a measurement of the inverse of the wound area remaining after 24 hours of incubation; 
normalized to the 0-hour negative control. (Lower Left) An example of each group from the assay: positive 
control, 5µM CDDP, 10µM CDDP, respectively. 
(Upper Right) This bar graph shows the average migration of TR127 cells after a 24-hour wound-healing 
assay as a measurement of the inverse of the wound area remaining after 24 hours of incubation; 
normalized to the 0-hour negative control. (Lower Right) An example of each group from the assay: 
positive control, 10µM CDDP, 20µM cerulenin, 10µM CDDP + 20µM cerulenin, respectively. 
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The flow cytometry results even further supported our existing results that FAS plays a pivotal role in 
mediating CDDP resistance, as shown in figure 7. 
 
  
Control 
Quad  Events  %Gated %Total 
UL           416  4.16   3.98 
UR  616  6.16  5.89 
LL  8676  86.76  82.90 
LR  292  2.92  2.79 
CDDP 10µM 
Quad  Events    %Gated %Total 
UL  560  5.60  5.39 
UR  395  3.95  3.80 
LL  8981  89.81  86.41 
LR  64  0.64  0.62 
Cerulenin 20µM 
Quad  Events    %Gated   %Total 
UL  866  8.66  6.87 
UR  4028  40.28  31.96 
LL  4595  45.95  36.46 
LR  511  5.11  4.05 
CDDP 10µM + Cerulenin 20µM 
Quad   Events    %Gated   %Total 
UL  243  2.43  1.79 
UR  8414  84.14  61.99 
LL  182  1.82  1.34 
LR  1161  11.61  8.55 
Figure 7: Annexin V results obtained from TR127 cells cultured with RPMI medium (positive control), 10 µM 
CDDP, 20 µM cerulenin, or 10 µM CDDP + 20 µM cerulenin. The lower left quadrant represents viable, 
healthy cells. The upper left quadrant represents the percentage of necrotic cells stained with both annexin 
V and propidium iodide. The lower right quadrant represents cells beginning early apoptosis that are stained 
with only annexin V and the upper right quadrant represents cells already having undergone apoptosis, 
which are stained with only propidium iodide.CDP-treated cells underwent less apoptosis (3.95%) than did 
the control cells (6.16%); the combination treatment cells underwent significantly more apoptosis (84.14%). 
Results are shown as percentages that are averages of triplicates. 
Control CDDP 
10µM 
 
Cerulenin 20µM 
 
CDDP 10µM + 
Cerulenin 20µM 
 
6.16% 3.95% 
40.28% 84.14% 
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Cumulatively, these results demonstrate that levels of FAS are positively correlated with treatment 
with CDDP (up to 10µM) and that increased FAS is positively correlated with increased cell viability. 
While no mechanism has been specifically explored, the results support my hypothesis that FAS 
takes part in mediating CDDP resistance in ROCCs consequent of the upregulation of FAS 
stimulating one of the four resistance pathways mentioned earlier in this report, while simultaneously 
allowing the cell to meet its newfound metabolic demands. 
Discussion  
Fatty acid synthase is identified as the oncogenic antigen-519 (25) and it is now clear that FAS is 
highly expressed in a biologically aggressive subset of various human tumors, including ovarian 
cancers (26).  Endogenous FAS expression is extremely low in most normal human tissues, except 
lactating breast and cycling endometrium (5). Recent evidence shows that high levels of FAS are 
found to correlate with poor prognosis and survival for various cancers, including ovarian cancer (27, 
28).Cerulenin, a natural product, was the first specific inhibitor of FAS to be studied (29) and has 
been evaluated in a variety of human cancer cell lines and xenograft tumors. Current research is now 
highlighting inhibitors of the FAS pathway, such as cerulenin, as a potential drugs for targetted 
anticancer therapy.  
Drug resistance is a major clinical obstacle in creating a successful ovarian cancer chemotherapy. 
Recent research in vitro and in vivo suggests multiple molecular mechanisms of resistance identified 
in ovarian cancer, such as ABC transporter-mediated drug efflux and hypoxia-mediated oncogene 
activation (30). In addition, our pilot study identified a similar correlation between drug resistance and 
overexpression of fatty acid synthase in human tumor samples, as that seen in the resistant ovarian 
cell lines. Further, this study showed that overexpression of FAS is indeed correlated with drug 
resistance, inhibition of apoptosis, and and decreased migration in ovarian cancer cell lines. 
The molecular mechanism of FAS-mediated drug resistance in ovarian cancer is not yet known and 
the relationship between drug resistance and overexpression of FAS in ovarian cancer cells is poorly 
understood. Based upon previous research, FAS overexpression in drug resistant ovarian and breast 
cancer cells causes an overproduction of palmitate to increase resistance to anti-cancer drug-induced 
apoptosis (30). Another study showed that fatty acids synthesized by FAS in cancer cells are 
saturated and monounsaturated and, therefore, the increased lipid synthesis in cancer cells may 
change both the quantity of membrane lipids required for cell growth as well as the lipid composition 
of the membrane (31). 
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Conclusion 
Drug resistance in is a major impediment that prevents effective treatment of the leading cause of 
death amongst women, ovarian cancer. Resistance, specifically platinum resistance, is most often 
seen in recurrent ovarian cancer tissues and has been attributed to reduced cisplatin uptake or 
increased cisplatin efflux, glutathione-mediated cisplatin inactivation and detoxification, and increased 
DNA repair by nucleotide excision repair. FAS has been implicated in CDDP resistant ovarian cancer, 
is consistently found to be upregulated in these tissues, and is positively correlated with increased 
migratory ability and resistance to apoptosis. Our results support these ideas, showing that with 
increased CDDP exposure (up to 10M) there is a concurrent increase in intracellular FAS mRNA 
and protein expression. Additionally, it is shown that when the 10M dose, which normally contributes 
to increased migration and decreased apoptosis, is coupled with a small-molecule inhibitor or FAS, 
the cells undergo significant stress and eventually apoptosis. While the mechanism underlying the 
interaction between CDDP and FAS remains largely undefined, these results support the idea that 
FAS mediates resistance to common anticancer treatments. 
 
Ongoing and future direction 
Moving forward, we will use TR127 and TR182 (also a platinum-resistant line) cells to explore a more 
specific mechanistic understanding of the role FAS plays in mediating platinum resistance. Western 
blotting will be used to analyze upstream and downstream protein levels in the FAS pathway to allow 
us to confirm that FAS is indeed the main driving component behind CDDP resistance in ovarian 
cancer cells. Wound-healing assays will be reconfirmed and optimized by pretreating the TR127 cells 
with mitomycin C. This will allow us to specifically identify the effect of CDDP and cerulenin on cell 
migration by separating proliferation from migration. In addition, immunocytochemistry will be used to 
confirm differential FAS levels in various CDDP treatment concentrations as well as in those cells 
treated with cerulenin. Once this in vitro work is complete, orthotopic mouse models of ovarian cancer 
will be created to study the effect of cancer progression as a result of these treatments. Together, the 
results procured from these experiments will help us to confirm the potential of FAS being an effective 
target for anticancer therapy.  
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